<s id="fzjui"><acronym id="fzjui"><u id="fzjui"></u></acronym></s>

  1. <dd id="fzjui"><center id="fzjui"></center></dd>

    <nav id="fzjui"></nav>



    當前位置:首頁 >產品中心>細胞庫>人腫瘤細胞、癌細胞>CRL-188 LS 174T 人結腸腺癌細胞

    CRL-188 LS 174T 人結腸腺癌細胞

    簡要描述:CRL-188 LS 174T 人結腸腺癌細胞,原代細胞|細胞系|細胞株|菌種,細胞庫管理規范,提供的細胞株背景清楚,提供參考文獻和*培養條件!

    • 產品型號:
    • 廠商性質:生產廠家
    • 更新時間:2024-03-12
    • 訪  問  量:1855


    Product Category


    Related Articles


    CRL-188 LS 174T 人結腸腺癌細胞

    CRL-188 LS 174T 人結腸腺癌細胞

    ATCC® Number:  CL-188™

    Designations:  LS 174T

    Depositors:   Northwestern University

    Biosafety Level: 1

    Shipped:  frozen

    Medium & Serum:  See Propagation

    Growth Properties: adherent

    Organism: Homo sapiens (human)

    Morphology: epithelial

    Source: Organ: colon

    Tumor Stage: Dukes' type B

    Disease: colorectal adenocarcinoma

    Cellular Products: carcinoembryonic antigen (CEA) (The production of CEA in the ATCC seed stock was 1944 ng per 10(6) cells in 10 days.)

    interleukin 10 (IL-10) [22511]

    interleukin 6 (IL-6)


    Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimay responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

    Tumorigenic: Yes

    Reverse Transcript: negative

    Oncogene: myc +; myb + ; ras +; fos +; p53 +; sis -; abl -; ros -; src -

    Antigen Expression: serologically defined colon cancer antigen 3; Homo sapiens, expressed

    HLA A2, B13, B50; Blood type O

    Cytogenetic Analysis: 45,X; one X chromosome missing; no other chromosomal aberrations

    Isoenzymes:  ADA, 1

    ES-D, 1

    G6PD, B

    PEP-D, 1

    PGD, A

    PGM1, 1

    PGM3, 2

    Age:  58 years

    Gender:  female

    Ethnicity:  Caucasian

    Comments: LS 174T is a variant of LS 180 (ATCC CL-187) that has been maintained by using trypsin in the subculture protocol. It is more easily subc*ted than that parent line and, like LS 180, it is reported to produce large amounts of carcinoembryonic antigen (CEA).

    Electron microscopic studies revealed abundant microvilli and intracytoplasmic mucin vacuoles [Pubmed ID: 1262041].

    They are negative for p53 antigen expression, but positive for mRNA expression.

    LS 174T cells stain positively for cytokeratins.

    The line is positive for expression of c-myc, N-myc, H-ras, N-ras.

    Myb, and fos oncogenes.

    K-ras and sis oncogene expression were not detected.

    Propagation:  ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.

    Atmosphere: air, 95%; carbon dioxide (CO2), 5%

    Temperature: 37.0°C

    Subculturing:  Protocol:

    Remove and discard culture medium.

    Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.

    Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).

    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.

    Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.

    Add appropriate aliquots of the cell suspension to new culture vessels.

    Incubate cultures at 37°C.

    Subc*tion Ratio: A subc*tion ratio of 1:2 to 1:4 is recommended

    Medium Renewal: 2 to 3 times per week

    Preservation:  Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO

    Storage temperature: liquid nitrogen vapor phase

    Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2003

    recommended serum:ATCC 30-2020

    derived from same individual:ATCC CL-187

    References: 2148: Tom BH, et al. Human colonic adenocarcinoma cells. I. Establishment and description of a new line. In Vitro 12: 180-191, 1976. PubMed: 1262041

    3524: Tom BH, et al. Process of producing carcinoembryonic antigen. US Patent 4,228,236 dated Oct 14 1980

    22147: Chen TR, et al. Intercellular karyotypic similarity in near-diploid cell lines of human tumor origins. Cancer Genet. Cytogenet. 10: 351-362, 1983. PubMed: 6652615

    22511: Gastl GA, et al. Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int. J. Cancer 55: 96-101, 1993. PubMed: 8344757

    22861: Trainer DL, et al. Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int. J. Cancer 41: 287-296, 1988. PubMed: 3338874

    32265: Tsao H, et al. Novel mutations in the p16/CDKN2A binding region of the Cyclin-dependent Kinase-4 gene. Cancer Res. 58: 109-113, 1998. PubMed: 9426066

    32377: Shibata D, et al. Genomic instability in repeated sequences is an early somatic event in colorectal tumorigenesis that persists after transformation. Nat. Genet. 6: 273-281, 1994. PubMed: 8012390

    32794: Kutchera W, et al. Protaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc. Natl. Acad. Sci. USA 93: 4816-4820, 1996. PubMed: 8643486

    CRL-188 LS 174T 人結腸腺癌細胞



    • 產品:

    • 您的單位:

    • 您的姓名:

    • 聯系電話:

    • 常用郵箱:

    • 省份:

    • 詳細地址:

    • 補充說明:

    • 驗證碼:






    (周一至周日9:00- 19:00)

    • 掃一掃 微信咨詢

    Copyright©2024 上海復祥生物科技有限公司 All Right Reserved    備案號:滬ICP備10013034號-2     sitemap.xml
    技術支持:化工儀器網    管理登陸